ADPT new logo.jpg
Adaptive Biotechnologies Presents New Data During IDWeek Demonstrating the Capability of Its Immune Medicine Platform to Distinguish Between SARS-CoV-2 Infection and Vaccine Response and Detect Lyme Disease
October 02, 2021 13:15 ET | Adaptive Biotechnologies
Real-world data show T-Detect™ COVID can detect prior SARS-CoV-2 infection nearly 12 months after initial diagnosis in some patients New research demonstrates T-cell testing using T-cell receptor...
ADPT new logo.jpg
Adaptive Biotechnologies Launches Enhanced clonoSEQ® Assay Reports for Patients with Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status
September 30, 2021 07:30 ET | Adaptive Biotechnologies
SEATTLE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
ADPT new logo.jpg
Adaptive Biotechnologies Announces Grand Opening of State-of-the-Art Headquarters and Expands Footprint in Seattle
September 21, 2021 16:05 ET | Adaptive Biotechnologies
SEATTLE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
ADPT new logo.jpg
Adaptive Biotechnologies to Present New SARS-CoV-2 Data from its Immune Medicine Platform During IDWeek 2021
September 16, 2021 08:03 ET | Adaptive Biotechnologies
SEATTLE, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
ADPT new logo.jpg
Adaptive Biotechnologies to Present at the Morgan Stanley Global Healthcare Conference
September 07, 2021 17:15 ET | Adaptive Biotechnologies
SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
ADPT new logo.jpg
Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer
August 04, 2021 16:15 ET | Adaptive Biotechnologies
SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
ADPT new logo.jpg
Adaptive Biotechnologies Reports Second Quarter 2021 Financial Results
August 04, 2021 16:05 ET | Adaptive Biotechnologies
SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
ADPT new logo.jpg
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 4, 2021
July 12, 2021 16:05 ET | Adaptive Biotechnologies
SEATTLE, July 12, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
ADPT new logo.jpg
New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern
June 09, 2021 07:15 ET | Adaptive Biotechnologies
SEATTLE, June 09, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
ADPT new logo.jpg
Adaptive Biotechnologies Included in More than 20 Abstracts at ASCO and EHA 2021 Highlighting Expanding Use Cases for MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients
June 03, 2021 07:30 ET | Adaptive Biotechnologies
SEATTLE, June 03, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...